Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhiyang Pingfu Liquid (ZPFL) is a traditional Chinese medicine (TCM) compound formulation developed for the management of immune checkpoint inhibitor-related cutaneous adverse events (irCAEs). It is used as an integrative supportive care measure alongside standard Western therapies such as emollients, antihistamines, and topical corticosteroids. Clinical evidence from randomized controlled trials indicates that ZPFL significantly accelerates the resolution of skin lesions and reduces the requirement for both systemic and topical glucocorticoids in cancer patients experiencing treatment-induced rashes. The formulation is typically administered through both oral and topical routes to provide comprehensive symptom relief and improve quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhiyang Pingfu Liquid.